Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
Public ClinicalTrials.gov record NCT02496208. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I trial studies the side effects and best doses of cabozantinib s-malate and nivolumab with or without ipilimumab in treating patients with genitourinary (genital and urinary organ) tumors that have spread from where it first started (primary site) to other places in the body (metastatic). Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving cabozantinib s-malate and nivolumab alone or with ipilimumab works better in treating patients with genitourinary tumors.
Study identification
- NCT ID
- NCT02496208
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 152 participants
Conditions and interventions
Conditions
- Bladder Small Cell Neuroendocrine Carcinoma
- Bladder Squamous Cell Carcinoma
- Bladder Urothelial Carcinoma
- Clear Cell Renal Cell Carcinoma
- Invasive Bladder Plasmacytoid Urothelial Carcinoma
- Invasive Bladder Sarcomatoid Urothelial Carcinoma
- Invasive Sarcomatoid Urothelial Carcinoma
- Kidney Medullary Carcinoma
- Malignant Genitourinary System Neoplasm
- Malignant Solid Neoplasm
- Penile Carcinoma
- Penile Squamous Cell Carcinoma
- Renal Cell Carcinoma
- Renal Pelvis Urothelial Carcinoma
- Sarcomatoid Renal Cell Carcinoma
- Stage III Bladder Cancer AJCC v8
- Stage III Penile Cancer AJCC v8
- Stage III Renal Cell Cancer AJCC v8
- Stage III Renal Pelvis and Ureter Cancer AJCC v8
- Stage III Renal Pelvis Cancer AJCC v8
- Stage III Ureter Cancer AJCC v8
- Stage III Urethral Cancer AJCC v8
- Stage IV Bladder Cancer AJCC v8
- Stage IV Penile Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
- Stage IV Renal Pelvis and Ureter Cancer AJCC v8
- Stage IV Ureter Cancer AJCC v8
- Stage IV Urethral Cancer AJCC v8
- Ureter Urothelial Carcinoma
- Urethral Urothelial Carcinoma
Interventions
- Biopsy Procedure Procedure
- Biospecimen Collection Procedure
- Cabozantinib S-malate Drug
- Computed Tomography Procedure
- Echocardiography Test Procedure
- Ipilimumab Biological
- Magnetic Resonance Imaging Procedure
- Nivolumab Biological
Procedure · Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 22, 2015 (Actual)
- Primary completion
- Jul 30, 2027 (Estimated)
- Completion
- Jul 30, 2027 (Estimated)
- Last update posted
- Oct 15, 2026
2015 – 2027
United States locations
- U.S. sites
- 8
- U.S. states
- 4
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | — |
| Los Angeles General Medical Center | Los Angeles | California | 90033 | — |
| USC / Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| University of California Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| National Institutes of Health Clinical Center | Bethesda | Maryland | 20892 | — |
| NCI - Center for Cancer Research | Bethesda | Maryland | 20892 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02496208, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02496208 live on ClinicalTrials.gov.